VYNE

VYNE Therapeutics Inc. [VYNE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VYNE Stock Summary

Top 10 Correlated ETFs

VYNE

Top 10 Correlated Stocks

VYNE

In the News

VYNE Financial details

Company Rating
-
Market Cap
39.05M
Income
-28.45M
Revenue
424K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.25
Forward P/E
-
PEG
0.07
P/S
89.5
P/B
0.65
P/C
-
P/FCF
-1.32
Quick Ratio
2.43
Current Ratio
2.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.01
EPS next Y
-
EPS next Q
-
EPS this Y
-73.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-54.96%
Revenue last 5Y
-0.87%
Revenue Q/Q
-33.33%
EPS Q/Q
-90.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-156%
ROE
-139%
ROC
-2.37%
Gross Margin
100%
Oper. Margin
-8591%
Profit Margin
-8482%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.67-8.73
52W High
-95.09%
52W Low
-60.69%
RSI
30
Rel Volume
336.79
Avg Volume
108.25K
Volume
36.46M
Perf Week
-64.9%
Perf Month
-57.21%
Perf Quarter
-83.76%
Perf Half Y
-85.71%
-
-
-
-
Beta
1.464
-
-
Volatility
0.36%, 0.26%
Prev Close
-72.7%
Price
0.3931
Change
-73.26%

Something similar

Top by Market Cap
AMZN
GOOGL
VTI
ABEC.DE
APC.DE
Top Correlated ETFs
EWM
RDFI
ISHG
FXE
IYLD
Top Correlated Stocks
AHKSY
AYI
XIACF
KCLI
COMM
Similar Market Cap
LSK8.DE
IIGD
8111.HK
LADYLU.ST
AMPG

Company Profile

Healthcare Biotechnology
  • Volume Average 108.25K
  • Market Capitalization 39.05M
  • Employee 10
  • CEO Mr. David T. Domzalski
  • Headquarters Bridgewater,NJ,US
  • IPO Date 2018-01-25
  • Website https://www.vynetherapeutics.com

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.